These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 10469178)

  • 1. The impact of inhibitors on the cost of clotting factor replacement therapy in Haemophilia A in Canada.
    Chang H; Sher GD; Blanchette VS; Teitel JM
    Haemophilia; 1999 Jul; 5(4):247-52. PubMed ID: 10469178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW; Lee SY; Park SK
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA; Plosker GL
    Pharmacoeconomics; 2007; 25(12):1007-29. PubMed ID: 18047387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
    Steen Carlsson K; Astermark J; Donfield S; Berntorp E
    Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations.
    Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F
    Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
    Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
    N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
    Teitel JM
    Haemophilia; 1999 Sep; 5 Suppl 3():43-9. PubMed ID: 10597387
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
    Roberts HR
    Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemophilia. Treatment of patients with inhibitors: cost issues.
    Goudemand J
    Haemophilia; 1999 Nov; 5(6):397-401. PubMed ID: 10583526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors in haemophilia A: current management and open issues.
    Haya S; Moret A; Cid AR; Cortina V; Casaña P; Cabrera N; Aznar JA
    Haemophilia; 2007 Dec; 13 Suppl 5():52-60. PubMed ID: 18078398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor economics.
    Teitel J
    Semin Hematol; 2006 Apr; 43(2 Suppl 4):S14-7. PubMed ID: 16690371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic decision-making in inhibitor patients.
    Allen G; Aledort L
    Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and utilization of hemophilia A and B patients with and without inhibitors.
    Armstrong EP; Malone DC; Krishnan S; Wessler MJ
    J Med Econ; 2014 Nov; 17(11):798-802. PubMed ID: 25111634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of an acquired factor VIII inhibitor with sequential recombinant factor VIIa and FEIBA.
    Miranda GG; Rodgers GM
    Haemophilia; 2009 Jan; 15(1):383-5. PubMed ID: 18759746
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
    Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
    Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies.
    Baghaipour MR; Steen Carlsson K
    Eur J Haematol; 2015 Feb; 94 Suppl 77():30-7. PubMed ID: 25560792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.